Adele Gulfo Joins Tyra Biosciences Board, Bringing Vast Drug Development Experience

Tyra Biosciences Welcomes Adele Gulfo to Board of Directors

Tyra Biosciences, Inc., a prominent clinical-stage biotechnology firm specializing in next-generation precision medicines, has announced the appointment of Adele Gulfo to its Board of Directors. This strategic move comes as the company focuses on expanding its portfolio, particularly targeting significant opportunities within Fibroblast Growth Factor Receptor (FGFR) biology.

Adele Gulfo brings nearly thirty years of extensive experience in drug development and commercialization from her tenures at leading pharmaceutical companies, including Pfizer, AstraZeneca, Viatris, and Sumitomo Pharma. During her career, she has been a pivotal figure in the development and launch of several blockbuster medications, most notably LIPITOR® and CRESTOR®.

According to Todd Harris, CEO of Tyra Biosciences, Gulfo's arrival marks a significant boon for the company. "Adele is among the industry's top drug developers, and her wealth of knowledge in product commercialization will be instrumental as we continue to advance our precision medicine pipeline," he stated. He further emphasized her experience in launching pertinent therapies, highlighting her leadership in the introduction of ORGOVYX® for prostate cancer which aligns with Tyra's own late-stage development plans for TYRA-300.

In her most recent role as CEO of the Biopharma Commercial Unit for Sumitomo Pharma America Inc., Gulfo directed a comprehensive commercial and development portfolio across various therapeutic areas, including oncology and rare diseases. Her previous experience as the chief commercial officer at Sumitovant Biopharma also laid a strong foundation for her expertise in product launches and market expansion strategies.

Gulfo's impact at Pfizer was notable; she oversaw operations of the company's U.S. primary care business unit, which generated over $12 billion annually. Moreover, her vice president roles at AstraZeneca further enhance her diversified perspective, as she contributed to the strategic management of multi-billion-dollar cardiovascular products.

Ms. Gulfo holds a Bachelor of Science degree in Biology from Seton Hall University and an MBA in Marketing, graduating with the highest honors from Fairleigh Dickinson University. She also delved into post-graduate studies in molecular biology at the University of Medicine and Dentistry of New Jersey, initiating her career path.

As she steps into this new role, Gulfo expresses her enthusiasm towards Tyra Biosciences, remarking on the company’s potential to develop transformative precision drugs aimed at various cancers. "TYRA has great potential in areas like non-muscle invasive bladder cancer, where innovative treatment approaches are urgently required," she stated. With her proven track record, she indicates a strong commitment to working closely with Tyra's executive team and leveraging her experience to enhance the firm's initiatives.

Tyra Biosciences is dedicated to pioneering precision medicines capable of addressing significant unmet medical needs in oncology and beyond, driven by its in-house SNÅP platform. This platform allows for the rapid development of precise drug designs, making it a cornerstone of Tyra's business model and drug development strategies. The company’s lead product, TYRA-300, is positioned to be a first-in-class selective FGFR3 inhibitor, thus promising to avoid the toxic effects associated with broader FGFR inhibition.

This pivotal appointment not only fortifies Tyra’s leadership team but also signifies its commitment to enhancing its innovative capabilities as it strives to deliver next-generation medicines that promise to meet substantial market demands. Tyra Biosciences has a robust pipeline, evaluating TYRA-300 in multiple Phase 2 studies tailored to address severe health challenges, further establishing its role at the forefront of oncology therapeutics.

For more information regarding Tyra Biosciences and its ongoing projects, visit their official website at www.tyra.bio.